Me neither, so here is what I am reading for updates about the 32nd Annual JPMorgan Healthcare Conference.
Before arriving, hopefully you read the survival guide put forth by the InVivo blog team. In it, Chris Morrison and team outlined a few helpful talking points to help you when running in to industry colleagues.
Likewise, Luke Timmerman, from Xconomy, has all the industry news you need to know heading in to the event, perhaps most importantly; who he thinks should be buying attendees a drink!
Interested in a steady drum beat of real time updates about the event? Then check out Adam Feuerstein’s blog over at thestreet.com for his up to the minute coverage.
Another comprehensive look at the daily happenings can be found with Ron Leuty and his observations for the San Francisco Business Times.
So far, all of this positive investor sentiment, specifically related to the biotech industry, bodes well for the upcoming BIO CEO & Investor Conference February 10 -11 in New York City. The program’s Opening Plenary will feature portfolio managers and senior buy-side analysts as they discuss the results of this year’s Investor Perception Study, conducted by BIO’s Industry Analysis Team and International Strategy & Investment (ISI) as well as field a range of questions on the peaks and valleys of the 2014 landscape, from valuations and volatility to challenges and opportunities facing institutional investors today.
To learn more about the event program, including registration, visit here.